CBSA, Sen. Bennet host new FDA commissioner at life science roundtable

Wednesday August 23, 2017 0 comments Tags: Denver, Colorado BioScience Association, Sen. Michael Bennet, April Giles, Don Elliman, Scott Gottlieb

DENVER -- Colorado BioScience Association (CBSA) and Colorado Senator Michael Bennet introduced new U.S. FDA Commissioner Dr. Scott Gottlieb to Colorado’s life science sector Tuesday during an industry roundtable.CBSA_logoUSE

CBSA and Bennet co-hosted a roundtable discussion that included Gottlieb at the University of Colorado Anschutz Medical Campus covering topics including clinical trials, Breakthrough Therapy Designation, precision and regenerative medicine, the regulatory landscape for diagnostics, the digital health regulatory action plan, and the implementation of the 21stCentury Cures and MEDTECH acts.

Commissioner Gottlieb was appointed in May.

More than 60 of the state’s life science innovators, including CEOs, academic leaders and researchers shared their views on progress and the future outlook for the industry in Colorado at the roundtable discussion.

“It’s an honor for CBSA to co-host Dr. Gottlieb with Senator Bennet and introduce him to the dynamic industry leaders in our state,” said April Giles, CBSA president and CEO.

“His visit to Colorado highlights our state’s pioneering role in developing new cures and solving health care challenges. We also appreciate Senator Bennet’s leadership and the strong partnership he’s built with the FDA.

“Colorado is home to one of the fastest-growing bioscience sectors, leading the way on life-changing research and development,” said Bennet.

“Dr. Gottlieb's visit was an opportunity for researchers and innovators to engage with the FDA's leading voice in Washington. We look forward to continuing our work together to ensure lifesaving treatments make it to patients quickly and safely.”

“We’re happy to host Senator Bennet and Commissioner Gottlieb at the University of Colorado Anschutz Medical Campus, where we are pioneering bioscience collaboration every day,” said Don Elliman, chancellor of the University of Colorado Anschutz Medical Campus.

“The evolving health care landscape requires new models for innovation, and CU Anschutz is creating them. On our campus, the collaboration of the bioscience industry with our researchers and clinicians enables concepts to move from the research stage into practice, yielding breakthroughs in bioscience and real-world impacts on health care.”

Participants in the roundtable represented the state’s life science sector, with more than 720 companies and institutions that support 159,000 bioscience-related jobs.

The Anschutz Medical Campus and adjoining Fitzsimons Innovation Campus Bioscience Park Center are home to several of the state’s leading life science companies, research hospitals and institutions.

The Anschutz Campus is recognized as one of the nation’s leading medical complexes.